Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
13 November 2014Website:
http://soleno.lifeNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 21:08:30 GMTDividend
Analysts recommendations
Institutional Ownership
SLNO Latest News
REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia.
PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating Soleno Therapeutics, Inc. (NASDAQ:SLNO) ("Soleno") on behalf of the company's stockholders. The investigation seeks to determine whether Soleno and/or the company's officers and directors violated the securities laws or breached their fiduciary duties to the company's investors in connection with recent corporate actions.
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will participate in the following upcoming investor conferences:
The FDA has given Breakthrough Therapy Designation to diazoxide choline, which is significant for Soleno as it will speed up the review process for their main candidate.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Soleno Therapeutics, Inc. (SLNO) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Soleno Therapeutics, Inc. (SLNO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
An analyst changed his price target on the clinical-stage biotech. He added 10% to his level, which caught the market's attention.
Soleno announced on Tuesday top-line results for its lead therapy candidate. The company said it plans to submit a New Drug Application to the FDA regarding diazoxide choline controlled-release (DCCR) to treat Prader-Willi Syndrome.
The biotechnology company had announced positive study results for its DCCR tablets on Tuesday.
Soleno's (SLNO) shares rally as the late-stage study evaluating diazoxide choline for patients with Prader-Willi syndrome meets its primary and secondary endpoints.
What type of business is Soleno Therapeutics?
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
What sector is Soleno Therapeutics in?
Soleno Therapeutics is in the Healthcare sector
What industry is Soleno Therapeutics in?
Soleno Therapeutics is in the Biotechnology industry
What country is Soleno Therapeutics from?
Soleno Therapeutics is headquartered in United States
When did Soleno Therapeutics go public?
Soleno Therapeutics initial public offering (IPO) was on 13 November 2014
What is Soleno Therapeutics website?
https://soleno.life
Is Soleno Therapeutics in the S&P 500?
No, Soleno Therapeutics is not included in the S&P 500 index
Is Soleno Therapeutics in the NASDAQ 100?
No, Soleno Therapeutics is not included in the NASDAQ 100 index
Is Soleno Therapeutics in the Dow Jones?
No, Soleno Therapeutics is not included in the Dow Jones index
When does Soleno Therapeutics report earnings?
The next expected earnings date for Soleno Therapeutics is 08 August 2024